Business Wire

The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit

3.6.2023 08:11:00 EEST | Business Wire | Press release

Share

President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)

As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals.

“We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every big, complicated society is that there’s an incredibly built-in resistance to being the second, third, fourth, or 100th person to do the same thing, even though it’s been proven to work. Which is exactly the reverse of what we should be doing.”

Reflecting on his time in office during the 1990s, President Clinton said that we could learn much from the example of former South African President Nelson Mandela when it comes to uniting people behind a common cause for good.

“Everyone wants to believe they have some piece to add to life’s great puzzle,” he said. “You need converts to do anything big, and we’ve got to get more zealous converts. Nelson Mandela was a genius at this. He was the best I ever saw. He never tried to make people feel bad for what they hadn’t done. He tried to make people feel good about what they could do.”

Having long been a campaigner on the dangers of the opioid epidemic and a supporter of the PSMF since its inception, President Clinton suggested that it is important to focus on collaborating for future good rather than blaming and shaming when it comes to medical errors.

“No one wants to see innocent people die, and very few are hard-hearted enough not to care,” he said. “You don’t have to save everybody; you just have to save everybody that you can.”

Dr. Michael Ramsay, chief executive officer of the PSMF, told the audience that there is much cause for optimism when it comes to meeting the target of zero preventable deaths by 2030. “I think there’s a future now to patient safety,” he said. “I think things are going to start happening remarkably fast. Technology is changing, we’re gathering more data, and we’ve got more and more people involved in this movement.”

Jeremy Hunt, chancellor of the exchequer of the United Kingdom, delivered a video message to the Summit in which he applauded the difference made by the PSMF over the last decade. “We now have the World Health Organization doing an annual World Patient Safety Day, a 10-year plan to reduce preventable deaths, and we had a ministerial summit this year in Montreux in Switzerland with more than 100 countries represented. We’re making great progress, but there’s a lot of work to do. Even one preventable death is too many. We should be aiming for zero.”

Following on from President Clinton’s remarks about creating the right culture for change within healthcare, Anthony Staines, patient safety program director, Fédération des hôpitaux vaudois, Switzerland, described the need to address the failings of implementation science, a topic also addressed in a talk from Francisco Valero-Cuevas, a professor at the University of Southern California.

“There are many prevention and mitigation solutions, but they are only partly and unsystematically applied,” said Staines. “Science has brought us an expanding body of knowledge. The trouble is that it does not reach the patients.”

There were additional talks from Peter Ziese, chief medical officer at Philips, and Michelle Schreiber of the Centers for Medicare & Medicaid Services. Schreiber told the audience that while healthcare throughout the United States has made significant improvements in patient safety, the pandemic illustrated how our systems are still not durable and resilient enough for times of stress, and gaps in care and infrastructure continue to persist.

Mike Durkin and Sanaz Massoumi, chairman and chief operating officer of the PSMF respectively, gave addresses, and panel discussion topics included the media’s role in covering patient safety, opioid safety, and steps that can be taken in the journey to zero harm. Marcelo Ebrard Casaubón, secretary of foreign affairs of Mexico, received the Joe Kiani Humanitarian Award for his work in patient safety.

Finally, Kiani, founder of the PSMF, reflected on a decade of achievement and the path forward. “We started as a grassroots organization, and the grassroots movement has done so much,” he said. “I think our next step is to demand our elected officials to hardwire patient safety into our system and align the incentives so that every hospital puts evidence-based practices in place.”

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye